ODINSIGNAL JOURNAL · NEWS & EVENTS
FDA Target Date Set for ivonescimab Decision on Nov 14 2026
The FDA has a goal date of November 14 2026 for a decision on TEVA’s ivonescimab in non‑small cell lung cancer, according to the PDUFA calendar.
At a glance
- Date
- November 14, 2026
The U.S. Food and Drug Administration’s PDUFA calendar lists a November 14 2026 goal date for ivonescimab, TEVA’s candidate for non‑small cell lung cancer see the calendar. The entry appears alongside other upcoming targets, indicating the agency’s scheduled review window rather than a guaranteed outcome. No approval or complete response letter has been issued yet, so stakeholders will watch the deadline for any official FDA action.
FOLLOW THE EVENT
What happens next?
Explore the event, review its rules, and share your prediction on OdinSignal.
Explore the prediction market →Virtual credits only. No cash value.More from the Journal
Summit Therapeutics’ ivonescimab receives FDA PDUFA goal date of Nov 14 2026
Summit Therapeutics’ ivonescimab (HARMONi) BLA has a FDA PDUFA goal action date of November 14 2026 for non‑small cell lung cancer.
Read article →OPEC to Hold 42nd Ministerial Meeting on 29 November 2026
OPEC and non‑OPEC participating countries will convene on 29 Nov 2026 for the 42nd Ministerial Meeting, reaffirming the current crude‑oil production framework.
Read article →U2’s 16th Studio Album ‘Carnaval De Luz’ Set for November 13, 2026 Release
Island Records confirms U2’s new album ‘Carnaval De Luz’ will drop on November 13, 2026, marking their first studio album of new material in nine years.
Read article →Prediction markets express uncertainty, not established outcomes. OdinSignal uses virtual credits with no cash value.